A plant-derived compound, Lespedezaflavanone H, has been found to slow an enzyme called PRMT4 at a concentration of about 1.73 micromolar, and to restrain the growth of colorectal cancer cells grown in the laboratory. The work, published in Scientific Reports, belongs to a long human search through the natural world for molecules that might quiet disease, a search that often begins with a single promising number and a great deal of patient testing. Whether this modest signal in a dish will travel into living bodies remains, for now, an unanswered question.
Natural Flavanone Lespedezaflavanone H Shows PRMT4 Inhibition and Activity Against Colorectal Cancer Cells
The most sensitive line needed 2.32 µM; the least, 11.26 µM
Mark
What's the headline here, in plain terms?
Mimi
A plant-derived flavanone, Lespedezaflavanone H, blocked the enzyme PRMT4 at 1.73 micromolar and slowed the growth of four colorectal cancer cell lines.
Mark
Why PRMT4 specifically?
Mimi
The authors describe it as a newer target for anticancer drugs, with inhibitors seen as a promising option for colorectal cancer.
Luke
Promising is the authors' framing, though. What has actually been shown?
Mimi
Enzyme inhibition, predicted binding, simulations, and cell proliferation assays. That's the full list.
Luke
So the hydrogen bonds with ASN-265 and ARG-267 are predictions?
Mimi
Yes, from docking. The simulations suggest the binding stays stable, but that is still computational.
Mark
And the cell results?
Mimi
IC50s ranged from 2.32 micromolar in SW620 to 11.26 in LS180, so sensitivity varied quite a bit between lines.
Luke
Worth saying plainly: no animal or clinical data are reported, and selective is the authors' description. Cell lines don't settle whether this works in a patient.
Mimi
Agreed. Next is animal validation.
The Pulse
- A single plant compound cut PRMT4 enzyme activity in half at 1.73 micromolar, drawing attention to a relatively new target in colorectal cancer research.
- The compound slowed the growth of four colorectal cancer cell lines, with SW620 cells responding most strongly and LS180 cells needing about five times more of it.
- Researchers used molecular docking and dynamics simulations to map how the compound grips the enzyme, pointing to specific bonds with ASN-265 and ARG-267.
- The findings remain confined to enzyme assays, computer models and cell cultures, with no animal or human testing yet reported, so the path toward treatment is still open and uncertain.
A plant-derived compound, Lespedezaflavanone H, has been found to slow an enzyme called PRMT4 at a concentration of about 1.73 micromolar, and to restrain the growth of colorectal cancer cells grown in the laboratory. The work, published in Scientific Reports, belongs to a long human search through the natural world for molecules that might quiet disease, a search that often begins with a single promising number and a great deal of patient testing. Whether this modest signal in a dish will travel into living bodies remains, for now, an unanswered question.
A single number sits at the center of this study: 1.73 micromolar. At that concentration, a compound extracted from plants, Lespedezaflavanone H, cut the activity of an enzyme called PRMT4 by half. The work, reported in Scientific Reports, comes from a search for new colorectal cancer drug candidates among natural flavanones, a family of plant compounds.
PRMT4 is a relatively new target in anticancer drug discovery, and the authors see inhibitors of this enzyme as a promising route against colorectal cancer. Their method was straightforward in principle: screen a series of natural flavanones and see which could block the enzyme. One compound stood out as both potent and selective.
The researchers then asked how it worked. Computer modeling predicted that the compound forms hydrogen bonds with two amino acids in the enzyme, and simulations suggested the resulting pairing remains stable over time. The compound was then tested on living colorectal cancer cells, where it slowed proliferation in four lines. SW620 cells were the most sensitive, while LS180 cells required roughly five times as much compound to respond.
The authors believe this is the first report of this compound acting against PRMT4 and against colorectal cancer cells. Still, the evidence stops at the laboratory bench. No animal or human experiments have been reported, so whether the compound could become a treatment is still unknown. The next thing to watch for is whether the effect holds in animal models.
A single number anchors this study: 1.73 micromolar. That is the concentration at which a plant-derived compound called Lespedezaflavanone H cut the activity of an enzyme known as PRMT4, protein arginine N-methyltransferase 4, by half. The result comes from a paper in Nature's open-access journal Scientific Reports, which reports on a search for new colorectal cancer drug candidates among natural flavanones.
PRMT4 has drawn attention as a relatively new target in anticancer drug discovery, and the authors position inhibitors of the enzyme as a promising option for treating colorectal cancer. Their approach was to take a series of natural flavanones, a family of plant compounds, and test each for its ability to inhibit PRMT4.
One compound stood out. Lespedezaflavanone H was described as both a potent and a selective PRMT4 inhibitor, with that IC50 of 1.73 µM. The authors then turned to computation to ask how it might work. Molecular docking predicted that the compound forms hydrogen bonds with two specific amino acids in PRMT4, ASN-265 and ARG-267. The team also examined the compound's chemical descriptors and its molecular electrostatic potential in depth.
Molecular dynamics simulations, which model how the compound and the enzyme behave together over time, indicated that the PRMT4 and Lespedezaflavanone H complex held a stable binding mode.
The work did not stop at the enzyme. The researchers also tested the compound on living colorectal cancer cells, and it inhibited proliferation in four cell lines. The IC50 values were 3.93 µM for RKO, 2.32 µM for SW620, 5.68 µM for COLO 205 and 11.26 µM for LS180. SW620 was the most sensitive of the four, and LS180 the least, requiring roughly five times the concentration.
The authors state that, to the best of their knowledge, this is the first report of Lespedezaflavanone H acting as a PRMT4 inhibitor and showing antiproliferative activity against colorectal cancer cells.
The limits of the evidence matter here. The findings rest on enzyme assays, docking, simulations and cell-line experiments. Nothing in the report shows testing in animals or people, so whether the compound could become a treatment is an open question. The next evidence to watch for is whether the effect holds up in animal models.
Notable Quotes
The authors say this is, to their knowledge, the first report of Lespedezaflavanone H acting as a PRMT4 inhibitor with antiproliferative activity against colorectal cancer cells.— Study authors, Scientific Reports
Want the full story?
Read the original at Nature ↗
Health & Medicine